AU Patent

AU2024227421A1 — Cladribine regimen for use intreating progressive forms of multiple sclerosis

Assigned to Merck Patent GmbH · Expires 2024-11-07 · 2y expired

What this patent protects

of the invention: The present invention relates to the use of specific oral dosings, specific oral dosage forms and/or specific oral dose regimens comprising Cladribine for the treatment of progressive forms of Multiple Sclerosis, especially Primary Progressive Multiple Sclero…

USPTO Abstract

of the invention: The present invention relates to the use of specific oral dosings, specific oral dosage forms and/or specific oral dose regimens comprising Cladribine for the treatment of progressive forms of Multiple Sclerosis, especially Primary Progressive Multiple Sclerosis and/or Secondary 5 Progressive Multiple Sclerosis, and methods of treatment based thereon. 21238630_1 (GHMatters) P113483.AU.1

Drugs covered by this patent

Patent Metadata

Patent number
AU2024227421A1
Jurisdiction
AU
Classification
—
Expires
2024-11-07
Drug substance claim
No
Drug product claim
No
Assignee
Merck Patent GmbH
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.